Lian-Chun Xiao

Medicine & Life Sciences

1. Survival 100%
2. Hepatocellular Carcinoma 71%
3. Neoplasms 61%
4. Progression-Free Survival 55%
5. Acute Myeloid Leukemia 52%
6. Esophageal Neoplasms 43%
7. Drug Therapy 41%
8. Pancreatic Neoplasms 37%
9. Therapeutics 36%
10. Carcinoma 35%
11. venetoclax 34%
12. Biomarkers 33%
13. Confidence Intervals 32%
14. Renal Cell Carcinoma 32%
15. Positron-Emission Tomography 31%
16. Adenocarcinoma 30%
17. Clear-cell metastatic renal cell carcinoma 29%
18. Colorectal Neoplasms 28%
19. Neoplasm Metastasis 28%
20. Cytarabine 26%
21. Nivolumab 25%
22. B-Cell Chronic Lymphocytic Leukemia 24%
23. Somatomedins 23%
24. Liver Neoplasms 23%
25. Precursor Cell Lymphoblastic Leukemia-Lymphoma 21%
26. fludarabine 21%
27. Nomograms 20%
28. Idarubicin 20%
29. Protein-Tyrosine Kinases 20%
30. Prostatic Neoplasms 20%
31. pazopanib 19%
32. Biliary Tract Neoplasms 18%
33. GATA2 Deficiency 17%
34. gemcitabine 17%
35. Liver 17%
36. Breast Neoplasms 16%
37. Recurrence 16%
38. Urinary Bladder Neoplasms 15%
39. Induced Hyperthermia 15%
40. Nipple Aspirate Fluid 15%
41. Genes 15%
42. Bevacizumab 15%
43. Clinical Trials 15%
44. ramucirumab 14%
45. Clofarabine 14%
46. Esophagogastric Junction 14%
47. Castration 14%
48. Induction Chemotherapy 14%
49. Desmoplastic Small Round Cell Tumor 13%
50. Vascular Endothelial Growth Factor Receptor 13%